By
Trending Posts
Could Eli Lilly’s $1.3 Billion GPCR Deal with Superluminal Medicines Unlock a…
Key Highlights Eli Lilly Taps AI-Powered Drug Discovery in Landmark GPCR Agreement Eli Lilly has entered a global…
How Will Bayer’s $1.3 Billion Bet on KRAS G12D…
Key Highlights Bayer Targets KRAS G12D Mutation with Landmark Licensing Deal Bayer has entered a global exclusive licensing…
Can GSK’s Gepotidacin Priority FDA Review and Strategic…
Key Highlights: FDA Priority Review of Gepotidacin for GonorrhoeaGSK submitted a supplemental New Drug Application for gepotidacin, targeting…
Why Is Eli Lilly’s 2025 Outlook Soaring Despite…
Key Highlights: Strong Sales Growth and Raising GuidanceEli Lilly posted impressive Q2 2025 earnings surpassing estimates, largely on…
Why Could Novartis’ Ianalumab, With Dual Mechanism of B-Cell Depletion and BAFF-R…
Key Highlights: Positive Phase III Results Confirm Efficacy in Sjögren’s DiseaseThe NEPTUNUS-1 (275 patients) and NEPTUNUS-2 (504 patients)…
Can AstraZeneca’s $50 Billion U.S. Investment and Drug…
Key Highlights: Strategic Response to U.S. Pricing PressuresAstraZeneca CEO Pascal Soriot announced proactive proposals for U.S. drug price…
How Google Med-Gemini’s “Basilar Ganglia” AI Hallucination Signal a Wake-Up Call for…
Key Highlights: AI Hallucination: The “Basilar Ganglia” ErrorGoogle’s Med-Gemini suite, designed to summarize health data and generate radiology…
Can XtalPi & DoveTree’s $6 Billion AI Partnership…
Key Highlights: Strategic Overview: Industry’s Largest AI-Pharma CollaborationThis collaboration—one of the biggest in AI-driven drug discovery—combines XtalPi’s robust…
Will CMS’s 2026 WISeR AI Pilot Shift Traditional…
Key Highlights: AI-Powered Prior Authorization: New Model and ScopeCMS’s WISeR (Wasteful and Inappropriate Service Reduction) program introduces AI…
Trending Posts
Latest Stories
Can Amgen and Kyowa Kirin’s Rocatinlimab Redefine Atopic Dermatitis Care With Long-Term Safety and Sustained Efficacy in Over 2,600 Patients?
Key Insights: Breakthrough Data From ASCEND Long-Term Extension Amgen and Kyowa Kirin released top-line results…
Lilly’s Jaypirca Shows Strong Phase 3 Results in Untreated CLL/SLL
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN…
Could Immix Biopharma’s Strategic Investment by Goose Capital Accelerate Breakthrough CAR-T Therapies for AL Amyloidosis?
Key Highlights: Strategic Investment Signals Confidence in Immix’s Mission Immix Biopharma (Nasdaq: IMMX), a clinical-stage…
Is Novartis’ $1.4 Billion Acquisition of Tourmaline Bio a Game-Changer for Cardiovascular Inflammation Therapies?
Key Highlights A $1.4 Billion Bet on Cardiovascular Innovation Novartis announced its agreement to acquire…
Gallery
